SKYE Logo.png
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
June 10, 2024 07:00 ET | Skye Bioscience, Inc.
SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile; program discontinued Phase 2 study of Nimacimab in obesity expected to start in Q3 2024 Cash runway extended into...
SKYE Logo.png
Skye Bioscience to Present at Jefferies Global Healthcare Conference
June 03, 2024 07:00 ET | Skye Bioscience, Inc.
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
SKYE Logo.png
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
May 10, 2024 07:00 ET | Skye Bioscience, Inc.
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...
SKYE Logo.png
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
April 30, 2024 07:00 ET | Skye Bioscience, Inc.
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
SKYE Logo.png
Skye Bioscience to Present at Upcoming Investment Conferences
April 23, 2024 07:00 ET | Skye Bioscience, Inc.
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
SKYE Logo.png
Skye Bioscience Uplists to The Nasdaq Global Market
April 10, 2024 08:00 ET | Skye Bioscience, Inc.
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...
SKYE Logo.png
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
March 04, 2024 07:00 ET | Skye Bioscience, Inc.
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...
SKYE Logo.png
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
February 26, 2024 07:00 ET | Skye Bioscience, Inc.
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and...
SKYE Logo.png
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
December 11, 2023 07:00 ET | Skye Bioscience, Inc.
Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. ...
SKYE Logo.png
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
November 28, 2023 07:00 ET | Skye Bioscience, Inc.
SBI-100 Ophthalmic Emulsion, a CB1 agonist/activator delivered as a topical eye drop, was developed to treat patients with elevated intraocular pressurePhase 2 study evaluating efficacy and safety...